Minimum Information Model for Reporting
|
|
|
- Brandon Kennedy
- 8 years ago
- Views:
Transcription
1 Minimum Information Model for Reporting Dr. H. Sefiani - Pr. R. Soulaymani Bencheikh 1
2 Background WHO created the Department Safety and vigilances with ambition to integrate all Health Vigilances that allow the interplay various safety issues affecting patients 2
3 3
4 Reporting cornerstone of any vigilance system It is important to Collect as many reporting cases as possible (Quantity) Capture information on AEs in a structured manner and to the highest possible quality standards to: Enable causality assessment and preventability evaluation Build an efficient database Support accurate detection and analysis of signals Put in place Risk Minimisation Actions 4
5 Tools Terminologies, taxonomies and procedures should be harmonized To optimize communication To share data across systems To minimize the risks of inefficient use of resources especially for developing countries 5
6 Problematic Product used by patient: numerous and complex vigilance systems Each vigilance develop its own system: Specific reporting form Specific information Data collection, data extraction Dissemination Feedback 6
7 7
8 Old version: too long and not adapted to all Medicinal Products 8
9 Specific reporting forms: numerous 9
10 Limits For vigilance systems: Conception and production of several reporting forms Separated vigilances without any coordination Duplicated systems: logistic, distribution and availibility For reporters Several reporting forms Several interlocutor 10
11 Underreporting and lack of informations 11
12 Proposed Solution Adapting reporting form to satisfy reporters and to enhance the performance of the Pharmacovigilance System 12
13 Intergrated approach Reporting form with minimal common informations Global data base Global analysis Share informations for the consolidated learning around a patient safety incident 13
14 How?? Analysing the overlaps, redundancies and synergies across reporting and vigilances systems Creating model that will allow the seamless convergence of information 14
15 Standard reporting form Patient (report Id) AE/Incident Medicinal product: suspected and concomittent Context /circumstances Reporter (to have more information) 15
16 Invariable data Patient s data Name or initials Age or Date of Birth Sex Weight Origin: urban /rural Profession Relevant medical history Incident/AE data (Yes/No) Clinical description - Severity Date of onset End date Actions taken Outcomes Reporter Name Function : public / health professional Address, phone or . 16
17 Health products Variable Data Context/circomstances Medicines, vaccines and combined oral contraceptives Diagnostic radiology products Biological products Medical devices Dietary products and food additives Herbals Homeopathic products Cosmetics products Veterinary products Normal conditions of use Medication errors Treatment failure Drug-drug interactions Dependance Resistance Abuse, misuse Intoxications Toxicomany Defectiveproductsor counterfeit products 17
18 Health products Variable Data Context/circomstances Medicines, vaccines and combined oral contraceptives Diagnostic radiology products Biological products Medical devices Dietary products and food additives Herbals Homeopathic products Cosmetics products Veterinary products Normal conditions of use Medication errors Treatment failure Drug-drug interactions Dependance Resistance Abuse, misuse Intoxications Toxicomany Defectiveproductsor counterfeit products Before and After marketing Authorization, During medical practice and pharmacoepidemiolgical studies 02/10/2014 WithFirst or EMR/arab without meeting harm 18
19 Common Items for all Health products Name: brand and commun Indication/ reason for use Dose Route Duration : Start and stop date Action taken (withrawn, dose reduced ) 19
20 Vaccine Batch number Dose number (1st, 2nd..) Site of administration Vaccination session (public or private..) AEFI category Herbals Medical devices Cosmetics 02/10/2014 First EMR/arab meeting 20
21 Herbals Vernacular name Common name Part of herb Type of extraction Type of preparation Cosmetics Reason of use Dose (raw material) 02/10/2014 Vaccines First EMR/arab meeting Medical devices 21
22 Medical devices Brand name Model Type Batch number Location of use The user or manipulator Name and address of the manufacturer Incident (with or without harm) Vaccines Incident category Herbals 02/10/2014 First EMR/arab meeting Cosmetics 22
23 Cosmetics Site of application Time of application Reason of use Expery date Herbals Medical devices Vaccines 02/10/2014 First EMR/arab meeting 23
24 Reporting Form in Practice Hard/paper version, must be Unique Attractive, Simple Targeted information requested Short (1 page) Space for answers Possibility to contact reporter for specific items 24
25 National Pharmacovigilance Centre REPORTING ADVERSE EVENTS OF DRUGS AND OTHER HEALTH PRODUCTS Patient Name: Age: Gender M / / F / / Unknown/ / Weight (Kg): If pregnant, gestation term: Locality/city: Phone number: Adverse(s) events(s) Clinical and paraclinical description of adverse event: Relevant medical history Current medical condition: Comorbidities: Previous history of allergy: yes / / No/ / Unknown / / If yes, please specify which drug: Date of start of reaction: / / / / Date of end of reaction: / / / / Occurrence delay: Hours / / Days / / Months / / Relevant laboratory test: Differential diagnosis eliminated: Action taken: Drug withdrawn / / Dose reduced / / Treatment of reaction (Please specify): Other: Seriousness: Hospitalization / / Prolonged hospitalization / / Outcome: Favorable / / Sequelae / / Not recovered / / Death / / Unknown/ / Drugs and other health products administered by patient Name and form Suspected/ concomitant drug Dosage and route of administration Batch number Date of therapy start Date of therapy end Indication Status of dispensing and use(*) Action taken (**) Please specify if it is: (*) Medical prescription: 1 Self medication: 2 Medication error: 3 Defective product: 4 Drug interaction: 5 (**) Drug withdrawn: a Dose reduced: b Dose increased: c Dose not changed: d Unknown: e If vaccine: Number of administration: Setting of administration: Public sector /_/ Private sector /_/ Vaccination drive /_/ If herbal medicine: Quantity: Part used: Preparation: Infusion / / Decoction / / Soaking / / Other / / Rechallenge with drug or health product: Yes / / No / / Which one : Reccurence of adverse event: Yes / / No / / Please describe: Reporter Name: Tel: Postal address: Physician / / Specialist Dentist / / Pharmacist / / Nurse / / Other healthcare professional: Workplace: Teaching hospital / / Public sector / / Private sector/ / City:. Receive more information about this reporting: Yes / / No / / First EMR/arab meeting Signature To be transmitted by Post / Phone / Fax or 02/10/
26 Reporting Form in Practice Paper version Attractive, Simple Targeted informations requested Short (1 page) Space for answers Specific form should be available at the PV center Electronic version More exhaustive, but selective Attractive, Simple to fill Common data: first page Links for specific data Maximum: 10 min 26
27 Electronic version 27
28 Possible link for all specific data vaccines Herbals Cosmetics Medical devices Diagnostic radiology Biological products - Name of vaccine - Batch number - Dose number - Site of administration - Vaccination session - AEFI category - Vernacular name - Common name - Part of herb - Type of extraction - Type of preparation - Reason of use - Dose (raw material) - Name of product - Site of application - Time of application - Reason of use - Expery date - Manufacturer - Commercial name - Model - Type - Batch number - Location of use - the user or manipulator - name and address of the manufacturer - Incident Dietary products Homeopathic Veterinary 28
29 TERATOVIGILANCE DRUGS HERBAL COSMETIC Simple form Single form Single window/count 29
30 Future Vigilances delema Facilitate reporting act for reporters Built Pharmacovigilance performance As complete as possible As polyvalent as possible Integration of vigilances Facing challenges: Not duplicate systems: Rationalize resources Coordination between partners in Vigilances Harmonizing terminologies and definitions Developing a global system for vigilance 30
31 Thank you 31
PHARMACOVIGILANCE GUIDELINES
PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions
POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS
Health Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 3 Residential Care Facilities and Homes Standards of Practice Table of Contents 1. Application 2. Definitions 3. Supervision of Pharmacy Services in a Facility
GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
EphMRA Adverse Event Reporting Guidelines 2013
EphMRA Adverse Event Reporting Guidelines 2013 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS
TABLE OF CONTENTS CHAPTER 9 PATIENT COUNSELING AND PROSPECTIVE DRUG USE REVIEW REGULATIONS Section 1. Authority 9-1 Section 2. Definitions 9-1 Section 3. Patient Profile Records 9-1 Section 4. Prospective
EphMRA Adverse Event Reporting Guidelines 2015
EphMRA Adverse Event Reporting Guidelines 2015 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
The Changing Landscape
The Changing Landscape and J a r r o d M a l o n e, J D jmalone@hallrender.com WHAT WE WILL TALK ABOUT TODAY Medical and legal issues for physicians best practices Reducing liability Medical Malpractice
Medication Management Guidelines for Nurses and Midwives
Medication Management Guidelines for Nurses and Midwives 1. Introduction As the statutory body responsible for the regulation of nursing and midwifery practice in Western Australia (WA), the Nurses & Midwives
Humulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
How To Prevent Medication Errors
The Academy of Managed Care Pharmacy s Concepts in Managed Care Pharmacy Medication Errors Medication errors are among the most common medical errors, harming at least 1.5 million people every year. The
STANDARDS AND GUIDELINES TITLE: CIRCULATION DATE: March June 2013 REVISED: June 2013 APPROVAL DATE: July 29, 2013
College of Homeopaths of Ontario 163 Queen Street East, 4 th Floor, Toronto, Ontario, M5A 1S1 TEL 416-862-4780 OR 1-844-862-4780 FAX 416-874-4077 www.collegeofhomeopaths.on.ca STANDARDS AND GUIDELINES
Understanding Alberta s Drug Schedules
Understanding Alberta s Drug Schedules Preface In May 2002, the provincial drug schedules to the Pharmaceutical Profession Act were amended. In April 2007, the Alberta Regulation 66/2007 to the Pharmacy
Roles and Responsibilities Policy
Roles and Responsibilities Policy Contents Policy... 2 Scope/Audience... 2 Associated Documents... 2 Definitions... 2 Accountability... 2 Scope of Practice Statement:... 2 Anaesthetic Technicians... 3
ARIZONA. Downloaded January 2011
ARIZONA Downloaded January 2011 R9 10 101. DEFINITIONS 24. "Health care institution" means every place, institution, building or agency, whether organized for profit or not, which provides facilities with
Plum Borough School District Nursing Services Department
Information Regarding the Student with an Allergy Student s Name Grade Homeroom Date Physician s Name Physician s Phone # Type of Allergy (Food, Bee, Wasp, Latex, Other: Specify): Type of Reaction: For
Standards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents
Health Professions Act BYLAWS SCHEDULE F PART 2 Hospital Pharmacy Standards of Practice Table of Contents 1. Application 2. Definitions 3. Drug Distribution 4. Drug Label 5. Returned Drugs 6. Drug Transfer
Professional Standards and Guidance for the Sale and Supply of Medicines
Professional Standards and Guidance for the Sale and Supply of Medicines About this document The Code of Ethics sets out seven principles of ethical practice that you must follow as a pharmacist or pharmacy
4. Emergency medical treatment due to injury or physical illness. 5. Hospitalization (Medical) due to injury or physical illness
MCCMH MCO Policy 9-321 CONSUMER, INCIDENT, ACCIDENT, ILLNESS, DEATH, OR ARREST REPORT MONITORING Date: 7/02/13 receive and review all Consumer Incident, Accident, Illness, Death or Arrest Reports for violations
Frequently Asked Questions (FAQs) Treatment Authorization Request (TAR) Restriction on Antipsychotic Medications for the 0-17 Population
Frequently Asked Questions (FAQs) Treatment Authorization Request (TAR) Restriction on Antipsychotic Medications for the 0-17 Population Prescriber FAQs Update January 22, 2015 1. What information is needed
A competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
Custodial Procedures Manual Table of Contents
Custodial Procedures Manual Table of Contents Page 1. Drug Policies and Procedures 1 A. Procurement of Prescription Drugs 1 i. Prescription drugs may only be accepted from 1 pharmacies and or practitioners.
Inhaled Corticosteroids and Diabetes Onset
Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression Journal Club October 13, 2010 By Anya Litvak, Kik Keiko Greenberg, and Jonathan Chrispin Background Inhaled corticosteroids are commonly
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
Glossary of terms used in Pharmacovigilance
Glossary of terms used in Pharmacovigilance Absolute risk Risk in a population of exposed persons; the probability of an event affecting members of a particular population (e.g. 1 in 1,000). Absolute risk
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of
Medical/Clinical Assistant CIP 51.0801 Task Grid
1 Secondary Task List 100 PHARMACOLOGY 101 Measure drug dosages using droppers, medicine cups, syringes, and other specialized devices. 102 Utilize correct technique to administer medications using the
Agency # 070.00 REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING
Agency # 070.00 REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING 09-00: PATIENT COUNSELING 09-00-0001--PATIENT INFORMATION, DRUG USE EVALUATION, AND PATIENT COUNSELING The intent of this regulation
SAFETY MONITORING of MEDICINAL PRODUCTS. Reporting system for the general public
SAFETY MONITORING of MEDICINAL PRODUCTS Reporting system for the general public SAFETY MONITORING of MEDICINAL PRODUCTS Reporting system for the general public n WHO Library Cataloguing-in-Publication
UW School of Dentistry Comprehensive Medication Policy
UNIVERSITY OF WASHINGTON SCHOOL OF DENTISTRY Subject: UW School of Dentistry Comprehensive Medication Policy Policy Number: Effective Date: December 2014 Revision Dates: June 2015 PURPOSE This policy provides
Mona Osman MD, MPH, MBA
Mona Osman MD, MPH, MBA Objectives To define an Electronic Medical Record (EMR) To demonstrate the benefits of EMR To introduce the Lebanese Society of Family Medicine- EMR Reality Check The healthcare
Unit/Standard Number. Proficiency Level Achieved: (X) Indicates Competency Achieved to Industry Proficiency Level
1 Secondary Task List 100 INTRODUCTION TO HEALTHCARE 101 Identify the roles and educational/credentialing requirements of various health care practitioners. 102 Describe the 's job description, personal
Keeping patients safe when they transfer between care providers getting the medicines right
PART 1 Keeping patients safe when they transfer between care providers getting the medicines right Good practice guidance for healthcare professions July 2011 Endorsed by: Foreword Taking a medicine is
Rainbows of Learning School Age Child Care Program At Frankford Township School
Rainbows of Learning School Age Child Care Program At Frankford Township School Parent/Guardian #1 Name: Address: Employer: Parent/Guardian #2 Name: Address: Employer: Child s Name: Birth date: Gender:
Nurse Initiated STI Treatment Code
Nurse Initiated STI Treatment Code Public Health and Clinical Services Division June 2012 FORWARD The Nurse Initiated STI Treatment Code establishes the competencies which must be achieved and criteria
Medicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
MARY T. INC. PROGRAM POLICY MANUAL
MARY T. INC. PROGRAM POLICY MANUAL POLICY Safe Medication Assistance and SECTION: 2-2C TITLE: Administration Policy REVISED BY: Jane Strobel, RN PAGE: 1of 6 APPLIES TO: All Services Operating Under Rule
LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER - SHREVEPORT MEDICAL RECORDS CONTENT/DOCUMENTATION
LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER - SHREVEPORT MEDICAL RECORDS CONTENT/DOCUMENTATION Hospital Policy Manual Purpose: To define the components of the paper and electronic medical record
Requirements for Drug Information Centres
FIP Pharmacy Information Section Requirements for Drug Information Centres Summary All countries should provide drug information services either independently or as part of a regional network. The service
Guideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
ADMINISTRATION OF MEDICATIONS POLICY
Policy 6.007. ADMINISTRATION OF MEDICATIONS POLICY It is the policy of Cooperative Educational Services (C.E.S.) that students who require any medications to be administered during school hours, including
PHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)
CHAPTER 61-03-02 CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE) Section 61-03-02-01 Definitions 61-03-02-02 Absence of Provider or Consulting Pharmacist
Recommended guidelines for. schools
Recommended guidelines for medication administration in schools Objective At the end of the session the nurses will be aware of the HAAD standards and roles and responsibilities of a nurse in medication
Issue: June 2009 PROFESSIONAL STANDARDS AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES
Issue: June 2009 PROFESSIONAL AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES PROFESSIONAL AND GUIDANCE FOR THE SALE AND SUPPLY OF MEDICINES CONTENTS Status of this document About this document 1 Pharmaceutical
Root cause analysis in context of WHO International Classification for Patient Safety
1 NHS Presentation to [XXXX Company] [Type Date] Root cause analysis in context of WHO International Classification for Patient Safety Dr David Cousins Associate Director Safe Medication Practice and Medical
CARSON PHYSICAL THERAPY, INC.
PATIENTS WITH WORKER'S COMPENSATION INSURANCE We are interested in providing you with the best and most effective care possible. In order to begin your Physical Therapy as soon as possible, we offer you
SAMPLE ANTIMICROBIAL STEWARDSHIP POLICY
SAMPLE ANTIMICROBIAL STEWARDSHIP POLICY FOR A LOCAL HEALTH DISTRICT OR NETWORK Purpose of this document The development of an official policy for Antimicrobial Stewardship (AMS) is a fundamental step towards
a) Each facility shall have a medical record system that retrieves information regarding individual residents.
TITLE 77: PUBLIC HEALTH CHAPTER I: DEPARTMENT OF PUBLIC HEALTH SUBCHAPTER c: LONG-TERM CARE FACILITIES PART 300 SKILLED NURSING AND INTERMEDIATE CARE FACILITIES CODE SECTION 300.1810 RESIDENT RECORD REQUIREMENTS
UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2014 October 1 st, 2014
UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2014 October 1 st, 2014 Department Name: Department of Pharmacy Department Director: Steve Rough, MS,
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY
NEWFOUNDLAND AND LABRADOR PHARMACY BOARD Standards of Pharmacy Practice. Standards for Hospital Pharmacies
NEWFOUNDLAND AND LABRADOR PHARMACY BOARD Standards of Pharmacy Practice Standards for Hospital Pharmacies Approved by the Newfoundland and Labrador Pharmacy Board January 11, 1998 Updated: June 16, 2007
Coverage level: Employee/Retiree Only Plan Type: EPO
This is only a summary. If you want more detail about your coverage and costs, you can get the complete terms in the policy or plan documents at www.dbm.maryland.gov/benefits or by calling 410-767-4775
ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5
European Medicines Agency June 1995 CPMP/ICH/377/95 ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT:
West Midlands Centre for ADRs. Jeffrey Aronson. Robin Ferner. Side Effects of Drugs Annuals. Editor Meyler s Side Effects of Drugs
Do we have a common understanding of medication errors? Editor Meyler s Side Effects of Drugs Jeffrey Aronson Co-editor: Stephens Detection and Evaluation of Adverse Drug Reactions Side Effects of Drugs
247 CMR: BOARD OF REGISTRATION IN PHARMACY
247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,
HEALTH REQUIREMENTS & SERVICES: MEDICAL TREATMENT
DESCRIPTOR TERM: Students Millard District Policy File Code: 6200 1 st Reading: 05-08-14 HEALTH REQUIREMENTS & SERVICES: MEDICAL TREATMENT Purpose The purpose of this policy is to authorize school personnel
Adverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
VIII. Dentist Crosswalk
Page 27 VIII. Dentist Crosswalk Overview The final rule on meaningful use requires that an Eligible Professional (EP) report on both clinical quality measures and functional objectives and measures. While
S.B. NO.2b72 JAN 2 2 2016
S.B. NO.b JAN 0 A BILL FOR AN ACT THE SENATE TWENTY-EIGHTH LEGISLATURE, 0 STATE OF HAWAII RELATING TO ADVANCED PRACTICE REGISTERED NURSES. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: SECTION.
PCNE Classification for Drug related problems
PCNE Classification for Drug related problems (revised 22-04-03 vm) V4.00 2003 Pharmaceutical Care Network Europe Foundation This classification can freely be used in Pharmaceutical Care Research and practice,
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System
Ontario Public Drug Programs, Ministry of Health and Long-Term Care Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System For the 2012-2013
Pain Management Regulations Affect More Than Pain Management Specialists January 2012. Of counsel to
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
DRUG INFORMATION SYSTEM REFERENCE GUIDE. Department of Health and Wellness Province of Nova Scotia
DRUG INFORMATION SYSTEM REFERENCE GUIDE Department of Health and Wellness Province of Nova Scotia Table of Contents EDUCATION AND TRAINING...1 EDUCATION... 1 THE DRUG INFORMATION SYSTEM...2 IMPLEMENTATION
SafetyFirst Alert. Errors in Transcribing and Administering Medications
SafetyFirst Alert Massachusetts Coalition for the Prevention of Medical Errors January 2001 This issue of Safety First Alert is a publication of the Massachusetts Coalition for the Prevention of Medical
How To Write An Eprescription In Dubai
Page 1 of 6 patient medical records and eligibility available at the moment of prescribing and dispensing the medication. Serving the insured population in Dubai What is an e-prescription? It is the computer-based
GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION
GUIDELINES GUIDELINES ON PREVENTING MEDICATION ERRORS IN PHARMACIES AND LONG-TERM CARE FACILITIES THROUGH REPORTING AND EVALUATION Preamble The purpose of this document is to provide guidance for the pharmacist
CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION
CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed
Ohio Department of Health Authorization for Student Possession and Use of an Asthma Inhaler In accordance with ORC 3313.716/3313.
Ohio Department of Health uthorization for Student Possession and Use of an sthma Inhaler In accordance with ORC 3313.716/3313.14 completed form must be provided to the school principal and/or nurse before
Important Questions Answers Why this Matters: What is the overall deductible? Are there other deductibles for specific services?
: VIVA HEALTH Access Plan Coverage Period: 01/01/2015 12/31/2015 This is only a summary. If you want more detail about your coverage and costs, you can get the complete terms in the policy or plan document
Patient Eligibility: Ontarians who are five years of age and older that have a valid Ontario Health Card.
Ontario Public Drug Programs, Ministry of Health and Long-Term Care Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health
Allergies / Adverse Reactions
Allergies / Adverse Reactions Allergy Management The gathering and documentation of allergy information is the responsibility of all licensed health professionals (Pharmacists, Nurses, Physicians, Allied
Delegation of Services Agreements Change in Regulations
Delegation of Services Agreements Change in Regulations Title 16, Division 13.8, Article 4, section 1399.540 was amended to include several requirements for the delegation of medical services to a physician
Pharmacy Technician Syllabus 14152
Pharmacy Technician Syllabus 14152 Dianne Rider 43745 180 th Street Hazel, SD 57242 Instructor Home Phone (605) 628-2103 Cell Phone (605) 881-3973 Email: dianne.rider@k12.sd.us Course Description Aim:
Office of Clinical Standards and Quality / Survey & Certification Group
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop C2-21-16 Baltimore, Maryland 21244-1850 Office of Clinical Standards and Quality / Survey
Please put above in a plastic Ziploc bag with your child s name on it.
Dear Parent(s), You have noted your child has medications related to an allergic reaction. The Stamford Museum & Nature Center s requirements for noted medications are as follows: Epi-pen requirements
DEFINITIONS: For purposes of this policy, the definitions included in this section apply:
STUDENTS Administrative Procedures 516A Administering Prescribed Medication in School Students may require prescribed medication at school in order to benefit from their educational experience. The following
Medical Information Checklist For Indian Youth Summer Camp
Medical Information Name (First): Name (Last): Birth date: Age: Sex: Parent or guardian: Home Relationship to camper: Second Parent or guardian (or spouse): Home Relationship to camper: Emergency Contact
St Bernard s Catholic School. Administration of Medicine Policy
St Bernard s Catholic School Page 1 of 10 The St Bernard s administration of medicine policy has been developed to ensure that children with medical needs have the same access to education as their peers
Enrolled Copy S.B. 55
Enrolled Copy S.B. 55 1 PHARMACEUTICAL DISPENSING AMENDMENTS 2 2014 GENERAL SESSION 3 STATE OF UTAH 4 Chief Sponsor: Evan J. Vickers 5 House Sponsor: Stewart Barlow 6 Cosponsors: Brian E. Shiozawa 7 Curtis
Outpatient Prescription Drug Benefit
Outpatient Prescription Drug Benefit GENERAL INFORMATION This supplemental Evidence of Coverage and Disclosure Form is provided in addition to your Member Handbook and Health Plan Benefits and Coverage
Coverage for: Individual Plan Type: PPO. Important Questions Answers Why this Matters:
This is only a summary. If you want more detail about your coverage and costs, you can get the complete terms in the policy or plan document at www.chpstudent.com or by calling 1-800-633-7867. Important
Overview: Beacon-EHR Vendor Technical Work Group Version 1.0 work products
Overview: Beacon-EHR Vendor Technical Work Group Version 1.0 work products This document provides an overview of each of the Beacon-EHR Vendor Technical Work Group work products developed between January
Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety
Measure #130 (NQF 0419): Documentation of Current Medications in the Medical Record National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
Important Questions Answers Why this Matters: What is the overall deductible?
Important Questions Answers Why this Matters: What is the overall deductible? Are there other deductibles for specific services? Is there an out of pocket limit on my expenses? What is not included in
11 MEDICATION MANAGEMENT
1 11 MEDICATION MANAGEMENT OVERVIEW OF MEDICATION MANAGEMENT Depending on the size, structure and functions of the health facility, there may be a pharmacy with qualified pharmacists to dispense medication,
Adherence to long term therapy and. Dr H. Sefiani CAPM hsefiani@gmail.com
Adherence to long term therapy and Pharmacovigilance Dr H. Sefiani CAPM hsefiani@gmail.com «patients often dissemble when they say they've taken their medecine» Hippocrate «improve patient adherence to
Ohio Department of Health Authorization for Student Possession and Use of an Epinephrine Autoinjector
Ohio Department of Health uthorization for Student Possession and Use of an Epinephrine utoinjector In accordance with ORC 3313.718/3313.141 completed form must be provided to the school principal and/or
NSW Adult Subcutaneous Insulin Prescribing Chart User Guide
NSW Adult Subcutaneous Insulin Prescribing Chart User Guide Adult Subcutaneous Insulin Prescribing Chart User Guide - 13 August 2013 Contents Target audience:... 1 Exceptions:... 1 1. Introduction... 2
MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY
MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY Academic Reference Standards of Pharm.-D Program College of Pharmacy-University of Hail May The Major shift in the health-care system
Abstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
Oregon Trail School District 46
Oregon Trail School District 46 Code: JHCD-AR(1) Adopted: 9/14/98 Readopted: 4/12/04 Orig. Code(s): JHCD-AR Administering Noninjectable Medicines to Students** Students may, subject to the provisions of
PPO Hospital Care I DRAFT 18973
This is only a summary. If you want more detail about your coverage and costs, you can get the complete terms in the policy or plan document at www.ibx.com or by calling 1-800-ASK-BLUE. Important Questions
Compass Rose Health Plan: High Option Coverage Period: 01/01/2015 12/31/2015
This is only a summary. Please read the FEHB Plan RI 72-007 that contains the complete terms of this plan. All benefits are subject to the definitions, limitations, and exclusions set forth in the FEHB
Pharmacy Program Pre-Test
Last Name: Pharmacy Program Pre-Test * For each question, put a check mark for the one option that you think is correct. 1. A pharmacist receives a security prescription from a known local medical group